Hemodynamic effects of HPMA copolymer based doxorubicin conjugate: A randomized controlled and comparative spectral study in conscious rats

References

• Algren DA, Ashworth A. 2015. Acute acepromazine overdose: clinical effects and toxicokinetic evaluation. J Med Toxicol 11:121–3.
   PubMedGoogle Scholar
• Bertinchant J, Polge A, Juan J, Oliva-Lauraire M, Giuliani I, Marty-Double C, et al. 2003. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta 329:39–51.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. 2004. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–54.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Zhang J, Honbo N, Karliner JS. 2010. Doxorubicin cardiomyopathy. Cardiology 115:155–62.
   PubMed Web of Science ®Google Scholar
• Cohen-Segev R, Francis B, Abu-saleh N, Awad H, Lazarovich A, Kabala A, et al. 2014. Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure. Acta Histochem 116:1342–9.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT, et al. 2012. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23:vii155–66.
   PubMed Web of Science ®Google Scholar
• Dharmani M, Mustafa MR, Achike FI, Sim M-K. 2007. Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur J Pharmacol 561:144–50.
   PubMed Web of Science ®Google Scholar
• Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. 2008. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity. Am J Clin Pathol 130:688–95.
   PubMed Web of Science ®Google Scholar
• Drawz PE, Babineau DC, Brecklin C, HE J, Kallem RR, Soliman EZ, et al. 2013. Heart rate variability is a predictor of mortality in chronic kidney disease: a report from the CRIC Study. Am J Nephrol 38:517–28.
   PubMed Web of Science ®Google Scholar
• Duncan R, Coatsworth JK, Burtles S. 1998. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer doxorubicin (PK1). Hum Exp Toxicol 17:93–104.
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ. 2010. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 62:272–82.
   PubMed Web of Science ®Google Scholar
• Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. 2014. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol 28:31.
   Web of Science ®Google Scholar
• Fox ME, Szoka FC, Fréchet JMJ. 2009. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res 42:1141–51.
   PubMed Web of Science ®Google Scholar
• Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, et al. 2013. Activation of the Mas receptor by angiotensin-(1–7) in the renin–angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 145:874–84.
   PubMed Web of Science ®Google Scholar
• Haddadian Z, Eftekhari G, Mazloom R, Jazaeri F, Dehpour AR, Mani AR. 2013. Effect of endotoxin on heart rate dynamics in rats with cirrhosis. Auton Neurosci 177:104–13.
   PubMedGoogle Scholar
• Hanton G, Eder V, Rochefort G, Bonnet P, Hyvelin JM. 2008. Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Exp Opin Drug Metab Toxicol 4:681–96.
   PubMed Web of Science ®Google Scholar
• Hopewell WJ, Duncan R, Wilding D, Chakrabarti K. 2001. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent. Hum Exp Toxicol 20:461–70.
   PubMed Web of Science ®Google Scholar
• Japundzic N, Grichois ML, Zitoun P, Laude D, Elghozi JL. 1990. Spectral analysis of blood pressure and heart rate in conscious rats: effects of autonomic blockers. J Auton Nerv Syst 30:91–100.
   PubMedGoogle Scholar
• Japundzic-Zigon N. 1998. Physiological mechanisms in regulation of blood pressure fast frequency variations. Clin Exp Hypertens 20:359–88.
   PubMed Web of Science ®Google Scholar
• Katzung BG, Masters SB, Trevor AJ. 2004. Basic and Clinical Pharmacology. New York, NY: Lange Medical Books/McGraw-Hill.
   Google Scholar
• Kedar U, Phutane P, Shidhaye S, Kadam V. 2010. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6:714–29.
   PubMed Web of Science ®Google Scholar
• Kopeček J, Kopečková P, Minko T, Lu ZR. 2000. HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50:61–81.
   PubMed Web of Science ®Google Scholar
• Kopeček J, Šprincl L, Lim D. 1973. New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. J Biomed Mater Res 7:179–91.
   PubMed Web of Science ®Google Scholar
• Lee VW, Harris DC. 2011. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 16:30–8.
   PubMed Web of Science ®Google Scholar
• Lončar-Turukalo T, Vasi? M, Tasi? T, Mijatovi? G, Glumac S, Baji? D, T, Vasić M, Tasić T, Mijatović G, Glumac S, Bajić D, et al. 2015. Heart rate dynamics in doxorubicin-induced cardiomyopathy. Physiol Meas 36:727–39.
   PubMed Web of Science ®Google Scholar
• López-Miranda V, Herradon E, González C, Isabel Martin M. 2010. Vascular toxicity of chemotherapeutic agents. Curr Vasc Pharmacol 8:692–700.
   PubMed Web of Science ®Google Scholar
• Malugin A, Kopečková P, Kopeček J. 2007. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release 124:6–10.
   PubMed Web of Science ®Google Scholar
• Mani AR, Montagnese S, Jackson CD, Jenkins SCW, Head IM, Stephens RC, et al. 2009. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 296:G330–8.
   PubMed Web of Science ®Google Scholar
• Miltenburg N, Boogerd W. 2014. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40:872–82.
   PubMed Web of Science ®Google Scholar
• Mitry MA, Edwards JG. 2016. Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int J Cardiol Heart Vasc 10:17–24.
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. 2012. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–25.
   PubMed Web of Science ®Google Scholar
• Patel VB, Zhong J-C, Grant MB, Oudit GY. 2016. Role of the ACE2/Angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circ Res 118:1313–26.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Anker SD, Chua TP, Szelemej JR, Piepoli M, Adamopoulos S, et al. 1997. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 79: 1645–50.
   PubMed Web of Science ®Google Scholar
• Ranpuria R, Hall M, Chan CT, Unruh M. 2008. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant 23:444–9.
   PubMed Web of Science ®Google Scholar
• Šarenac O, Lozić M, Drakulić S, Bajić D, Paton JF, Murphy D, et al. 2011. Autonomic mechanisms underpinning the stress response in borderline hypertensive rats. Exp Physiol 96:574–89.
   PubMed Web of Science ®Google Scholar
• Sawaya H, Sebag IA, Plana JC, Januzzi JL, KY B, Cohen V, et al. 2011. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375–80.
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, et al. 2009. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34:1629–36.
   PubMed Web of Science ®Google Scholar
• Sipola P, Vanninen E, Jantunen E, Nousiainen T, Kiviniemi M, Hartikainen J, et al. 2012. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy. Nucl Med Commun 33:51–9.
   PubMed Web of Science ®Google Scholar
• Stein AB, Tiwari IS, Thomas P, Hunt G, Levent C, Stoddard MF, et al. 2007. Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res Cardiol 102:28–41.
   PubMed Web of Science ®Google Scholar
• Stojičić S, Milutinović-Smiljanić S, Šarenac O, Milosavljević S, Paton JF, Murphy D, et al. 2008. Blockade of central vasopressin receptors reduces the cardiovascular response to acute stress in freely moving rats. Neuropharmacology 54:824–36.
   PubMed Web of Science ®Google Scholar
• Stuckey MI, Petrella RJ. 2013. Heart rate variability in type 2 diabetes mellitus. Crit Rev Biomed Eng 41:137–47.
   PubMedGoogle Scholar
• Teraoka K, Hirano M, Yamaguchi K, Yamashina A. 2000. Progressive cardiac dysfunction in adriamycin‐induced cardiomyopathy rats. Eur J Heart Fail 2:373–8.
   PubMed Web of Science ®Google Scholar
• Tomalova AB, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, et al. 2016. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia. J Control Release 223:1–10.
   PubMed Web of Science ®Google Scholar
• Tong J, Ganguly P, Singal P. 1991. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 260:H909–16.
   PubMed Web of Science ®Google Scholar
• Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al. 1999. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5:83–94.
   PubMed Web of Science ®Google Scholar
• Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R. 2005. Polymer therapeutics designed for a combination therapy of hormone‐dependent cancer. Angewandte Chemie 117:4129–34.
   Google Scholar
• Yeung TK, Hopewell JW, Simmonds RH, Seymour LW, Duncan R, Bellini O, et al. 1991. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl) methacrylamide conjugates: and experimental study in the rat. Cancer Chemother Pharmacol 29:105–11.
   PubMed Web of Science ®Google Scholar
• Yokoyama M. 2014. Polymeric micelles as drug carriers: their lights and shadows. J Drug Target 22:576–83.
   PubMed Web of Science ®Google Scholar